# Gujarat Themis Biosyn Ltd. will acquire a portfolio of anti-tuberculosis (TB) and anti-infective brands from Sanofi.

*business · news · 2026-04-24 · NDTV Profit*

## Key points

- Gujarat Themis Biosyn is acquiring 13 branded generic products from Sanofi for Euro 158 million.
- The acquired portfolio covers over 55 countries in Europe, Middle East, and Africa.
- No manufacturing facilities or employees will transfer, keeping the deal asset-light and capital-efficient.
- The transaction is expected to close by December 2026 and be EPS accretive for GTBL.

**Companies:** Gujarat Themis Biosyn Ltd.
**Countries:** France, India

[Read the full story on NDTV Profit](https://www.ndtvprofit.com/business/gujarat-themis-biosyn-share-price-today-company-to-acquire-sanofi-portfolio-for-rs-1-700-crore-11401548)

---

Canonical: https://newsio.io/n/c2c5861e-2099-48c2-a84b-955bf6287209/gujarat-themis-biosyn-ltd-will-acquire-a-portfolio-of-anti-tuberculosis-tb-and-a
Summarized by Newsio from NDTV Profit. https://newsio.io/how-it-works